1. Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New York City Monday, October 22, 2007

2. Endeavor DES System PC Technology Drug: Zotarolimus Stent Delivery System Driver Cobalt Alloy Stent

3. Endeavor Clinical Program Overview 9m 2yr 3yr 4yr 9m 2yr 3yr 4yr ENDEAVOR I ENDEAVOR II ENDEAVOR II CA ENDEAVOR III ENDEAVOR IV ENDEAVOR PK Single Arm First-in-Man (n=100) 4yr 1:1 RCT vs. BMS (E=598,D=599) PK (n=106) 3yr Continued Access Single Arm (n=296) 2yr 3:1 RCT vs. Cypher® (E=323,C=113) 2yr 1:1 RCT vs.Taxus® (E=773,T=775) 12mo Pharmacokinetic Study (n=43) 9mo Single Arm (n=99) 9mo ENDEAVOR Japan E-FIVE Open Label Single Arm (n=8000) US Post Approval PROTECT 1:1 RCT vs. Cypher (E=4400,C=4400) Open Label Single Arm Study (n=5000) Proposed Ongoing Premarket Safety and Efficacy Package 25,619 Patients

4. Primary Endpoint: TVF at 9 months Secondary Endpoints: In-segment % DS at 8 months; TLR and TVR at 9 months Drug Therapy: ASA and Clopidogrel/Ticlid >6 months Zotarolimus Dose: 10  g per mm stent length Endeavor IV Clinical Trial Design PI: Martin B. Leon Single De Novo Native Coronary Lesion Vessel Diameter: 2.5–3.5 mm Lesion Length: ≤ 27 mm Pre-dilatation required 1:1 randomization N = 1,548 patients 80 sites US Endeavor Stent n=774 Taxus Stent n=774 30d 6mo 4yr 3yr 2yr 9mo 12mo 8mo 5yr Clinical/MACE Angiography/IVUS QCA and IVUS Subset (328 total = 21.2%)

5. Endeavor IV Patient Flowchart Angio F/U (8 mo) 135/16482.3% Patients Enrolled N = 1548 Randomized Endeavor n = 773 Taxus n = 775 Angio F/U (8 mo) 144/164 87.8% Clinical F/U (9 mo) 758/773 98.1% Clinical F/U (9 mo) 749/77596.6% (12 mo) 749/773 96.9% (12 mo) 741/77595.6%

6. Endeavor IV 8 Month QCA Endeavor (144 pts) Taxus (135 pts) P value RVD (mm) 2.65  0.47 2.68  0.45 0.635 MLD (mm) In-stent 1.95  0.61 2.25  0.61 <0.001 In-segment% DS 1.80  0.55 1.98  0.56 0.008 % DS In-stent 26.41  19.74 16.09  17.99 <0.001 In-segment 32.28  17.02 26.61  15.52 0.004 Late loss (mm) In-stent 0.67  0.49 0.42  0.50 <0.001 In-segment 0.36  0.47 0.23  0.45 0.023

7. Endeavor IV Restenosis at 8 Months (QCA) Endeavor (144 pts) Taxus (135 pts) P value Binary Restenosis - % (#) In-stent 13.3 (19) 6.7 (9) 0.075 Proximal edge 3.6 (5) 3.8 (5) 1.000 Distal edge 0.7 (1) 1.000 In-segment 15.3 (22) 10.4 (14) 0.284

8. Endeavor IV Clinical Events at 30 days Endeavor (770 pts) Taxus (772 pts) P-Value Death (all) – % (#) 0.3 (2) 00.249 Cardiac Cardiac 0.1 (1) 00.499 MI (all) – % (#) 0.8 (6) 2.3 (18) 0.022 Q Wave Q Wave 0.3 (2) 0.1 (1) 0.624 Non Q wave Non Q wave 0.5 (4) 2.2 (17) 0.007 Death (cardiac) + MI (all) – % (#) 0.9 (7) 2.3 (18) 0.042 Stent Thrombosis (all) – % (#) 0.4 (3) 0.1 (1) 0.374 TLR – % (#) 0.4 (3) 0.8 (6) 0.507 TVR (non-TL) – % (#) 0 0.3 (2) 0.500 TVR – % (#) 0.4 (3) 0.9 (7) 0.342 MACE – % (#) 1.2 (9) 3.0 (23) 0.019 TVF – % (#) 1.0 (8) 3.0 (23) 0.010

9. Endeavor IV Primary Endpoint Result at 9 months Target Vessel Failure TVF Rate P for Non-Inferiority < 0.001 Δ=3.8% Taxus(n=54/749)Endeavor(n=50/758) 7.2% 6.6%

10. Endeavor IV Clinical Events at 12 months Endeavorn=749Taxusn=741P-Value Death (all) – % (#) 1.1(8)1.1(8)1.000 Cardiac Cardiac 0.5 (4) 1.000 MI (all) – % (#) 1.6 (12) 2.6 (19) 0.208 Q Wave Q Wave 0.3 (2) 0.1 (1) 1.000 Non Q wave Non Q wave 1.3 (10) 2.4 (18) 0.131 Death (cardiac) + MI (all) – % (#) 2.1 (16) 3.1 (23) 0.260 Stent Thrombosis (all) – % (#) 0.8 (6) 0.1 (1) 0.124 0-30 days 0-30 days 0.4 (3) 0.1 (1) 0.625 31-360days 31-360days 0.4* (3) 00.250 TLR – % (#) 4.5 (34) 3.2 (24) 0.228 TVR (non-TL) – % (#) 2.5 (19) 4.2 (31) 0.085 TVR – % (#) 6.3 (47) 6.7 (50) 0.753 MACE – % (#) 6.5 (49) 6.6 (49) 1.000 TVF – % (#) 7.7 (58) 9.4 (70) 0.267 *Day 83, 145, 171

11. TaxusEndeavor Freedom from TVF 100% 85% 0306090120150180210240270300330360 Time after Initial Procedure (days)TVF030180270360Endeavor773760737712670 Taxus775748721692655 90% 95% TVF-free92.3%90.6%0.243 EndeavorTaxusP (log rank) Endeavor IV TVF Free Survival to 360 days

12. Endeavor IV Target Vessel Revascularization Endeavor (41/758) Taxus (37/749) Endeavor (47/749) Taxus (50/741) P = 0.728 9 months 12 months Rate P = 0.753 5.4% 4.9% 6.3% 6.7%

13. Endeavor IV Target Lesion Revascularization Endeavor (31/758) Taxus (20/749) Endeavor (34/749) Taxus (24/741) P = 0.154 9 months 12 months Rate P = 0.228 4.1% 2.7% 4.5% 3.2%

14. Endeavor IV TLR by Angiographic Follow-up at 12 months TLR Rate 12/141 4/133 22/60820/608 EndeavorTaxusEndeavorTaxus Angiographic Follow-up Clinical Follow-up P =0.070 P =0.875

15. Endeavor IV - Diabetics TVF and TLR at 12 months Rate 20/233 24/223 16/23313/223 EndeavorTaxusEndeavorTaxus P =0.526 P =0.704 8.6% TVF TLR 477 diabetics (30.8% of E IV patients)

16. Endeavor IV TVF – Post Hoc Subgroup Analysis Risk Ratio [95% CI] Risk Ratio EndeavorTaxus P-Value Interaction 0.761.107.9%6.2%8.5%6.9%0.960 Diabetes Non-diabetes 0.821.130.81 7.3%7.2%5.5% 9.0%6.4%6.7%0.479 RVD  2.5mm >2.5 <3.0mm  3.0mm 0.651.190.53 4.4%8.0%5.8% 6.8%6.7%11.0%0.735 Lesion Length  10mm >10 10 <20mm  20mm 1.010.956.2%14.3%6.2%15.1%0.901 Single Stent Multiple Stents 0.1110 Favors Endeavor Favors Taxus

17. The Endeavor DES, compared with the Taxus DES, demonstrated… Endeavor IV Conclusions Reduced peri-procedural non-Q MIs, and a similar overall safety profile (death, Q-MI, and stent thrombosis) through 12 months follow-up Reduced peri-procedural non-Q MIs, and a similar overall safety profile (death, Q-MI, and stent thrombosis) through 12 months follow-up Higher angiographic late loss at 8 months follow-up Higher angiographic late loss at 8 months follow-up Similar TVF (1 ry endpoint) through 12 months follow-up Similar TVF (1 ry endpoint) through 12 months follow-up Similar TVR/TLR in subsets of interest (including diabetics) through 12 months follow-up, especially in the clinical FU patient cohort Similar TVR/TLR in subsets of interest (including diabetics) through 12 months follow-up, especially in the clinical FU patient cohort